US Tariffs

India and the US are engaged in discussions aimed at reaching a balanced and mutually beneficial trade agreement, said a spokesperson for the ministry of external affairs on Thursday

A refund system for businesses that paid tariffs which the US Supreme Court ruled President Donald Trump imposed without the constitutional authority to do so is scheduled to launch Monday. Importers and their brokers will be able to begin claiming refunds through an online portal beginning at 8 am, according to US Customs and Border Protection (CBP), the agency administering the system. It is the first step in a complicated process that also might eventually lead to refunds for consumers who were billed for some or all of the tariffs on products shipped to them from outside the United States. Companies must submit declarations listing the goods on which they collectively put billions of dollars toward the import taxes the court subsequently struck down. If CBP approves a claim, it will take 60-90 days for a refund to be issued, the agency said. The government expects to process refunds in phases, however, focusing first on more recent tariff payments. Any number of technical facto

India's marine exports rise nearly 14% in FY26 despite tariffs and war impact, while rice shipments decline amid weak prices and West Asia disruptions

IMF has raised India's FY27 growth forecast to 6.5 per cent, saying lower US tariffs could offset the impact of West Asia tensions even as global growth and trade outlook weaken

Indian delegation to visit US capital to advance interim trade pact discussions as both sides seek clarity on tariffs and non-tariff barriers

Amol Athawale of Kotak Securities believes that the short-term outlook for Nifty Healthcare remains uncertain and sentiment may turn negative in case the index falls below 13,500 levels.

Proposed US tariffs on patented drugs may pressure innovators to shift production locally, creating uncertainty for Indian CDMOs even as generics-led exports remain largely insulated

US tariffs on patented drugs may have limited immediate impact on India, but industry flags uncertainty as policy ties relief to pricing and manufacturing shifts

The US has announced a 100 per cent tariff on patented pharma imports from countries like India without reshoring deals, aiming to boost local production, while generics have been exempted for now

US plans 50% tariffs on many derivative goods, based on import value while others will face 25% duties, with some products taxed at even lower rates

India and the US are set to clash over WTO reforms ahead of the MC14 meeting, with New Delhi defending core principles like consensus decision-making and the MFN rule

India remains engaged with the US side for a mutually beneficial trade deal, says Commerce Secretary Rajesh Agrawal, as negotiations continue on tariff changes and non-tariff barriers

After the courts blocked earlier tariffs, the Trump administration turns to Section 301 probes to justify new duties-putting India and other major trading partners under scrutiny

The US Trade Representative has launched an unfair trade practices probe into 60 countries, including India, alleging failure to block imports of goods produced using forced labour

USTR opens Section 301 investigations into 16 economies, including India, over excess manufacturing capacity that Washington says undermines US industrial revival

US tariff relief restarts Dollar Town's knitting machines, revives stalled exports, yet the Iran curveball threatens to fray town's delicate recovery

Textile mills, engineering units, and sports goods makers across Ludhiana and Jalandhar test a fragile export revival

Every crease and fold tells the story of the city's leather industry, stretched thin by tariffs, disrupted consignments, and a fragile global market

Goyal said India is closely watching the evolving situation following the US SC's verdict, and will continue to engage with Washington for best possible opportunities in the interim trade deal

USTR says India will determine within six months of the interim pact coming into force whether US or international standards are acceptable for select sectors, easing market access for US exports